Zeo ScientifiX, Inc. (ZEOX)
- Previous Close
1.9800 - Open
2.0500 - Bid 2.0000 x 444600
- Ask 2.0500 x 50000
- Day's Range
2.0500 - 2.0500 - 52 Week Range
1.2500 - 4.7300 - Volume
1,259 - Avg. Volume
4,834 - Market Cap (intraday)
13.222M - Beta (5Y Monthly) 5.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8000 - Earnings Date Jun 12, 2025 - Jun 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company's lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body's natural ability to decrease cellular inflammation and promote tissue healing. In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROW X, a professional-grade formula that delivers a concentrated dose of topical exosomes that help support follicular function; ZEO GROW BOOST; and EXO FOLLICLE FUEL. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is headquartered in Davie, Florida.
www.zeoscientifix.comRecent News: ZEOX
View MorePerformance Overview: ZEOX
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZEOX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZEOX
View MoreValuation Measures
Market Cap
13.22M
Enterprise Value
13.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.87
Price/Book (mrq)
--
Enterprise Value/Revenue
2.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-107.73%
Return on Assets (ttm)
-169.83%
Return on Equity (ttm)
--
Revenue (ttm)
4.56M
Net Income Avi to Common (ttm)
-4.91M
Diluted EPS (ttm)
-0.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
720k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
589.38k